Allakos, Inc.
(NASDAQ : ALLK)

( )
ALLK After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.81%175.590.7%$1405.98m
PFEPfizer Inc. -1.83%50.400.9%$1327.23m
ABBVAbbVie, Inc. -1.44%152.551.9%$1169.95m
BMYBristol-Myers Squibb Co. -1.52%77.031.0%$1169.89m
MRKMerck & Co., Inc. -1.02%92.050.7%$1097.17m
LLYEli Lilly & Co. -1.98%295.431.1%$859.74m
AZNAstraZeneca Plc -3.53%63.321.0%$489.96m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. 0.09%141.900.0%$438.60m
VERUVeru, Inc. -3.78%15.010.0%$363.86m
NVSNovartis AG -0.27%87.680.2%$229.58m
GSKGlaxoSmithKline Plc -2.42%43.630.2%$222.90m
HZNPHorizon Therapeutics Plc -4.82%88.425.4%$193.67m
SGENSeagen Inc. -2.42%143.005.7%$174.55m
NVONovo Nordisk A/S -2.61%103.560.1%$171.61m
VTRSViatris, Inc. -1.74%11.270.0%$153.78m

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood City, CA.